Pipeline

Alevin’s preclinical pipeline features small molecules that target integrin receptors. 
Our broad intellectual property estate contains an array of inhibitors that are both potent and isoform-selective.

ALV296

A potent and selective inhibitor of the αvβ6 integrin under development as an inhaled drug treatment for idiopathic pulmonary fibrosis

ALV2007

A pan-integrin inhibitor, under development as an oral drug to treat liver and kidney fibrosis, and cancer

Discovery Programmes

We have multiple additional isoform-selective inhibitor programmes under development.

chevron-down